<DOC>
	<DOC>NCT01192698</DOC>
	<brief_summary>The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is removed)will have sustained virologic response post liver transplant.</brief_summary>
	<brief_title>Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>liver transplant for hepatitis c allergy to interferon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>hepatitis c</keyword>
	<keyword>liver transplant</keyword>
	<keyword>hepatitis C after liver transplant</keyword>
</DOC>